Posted by Michael Wonder on 18 Nov 2025
Vasa Therapeutics granted FDA fast track designation for VS-041, a novel investigational treatment of heart failure with preserved ejection fraction
18 November 2025 - Vasa Therapeutics today announced that the US FDA has granted fast track designation to its lead investigational therapy,
VS-041, a narrow spectrum small molecule inhibitor of matrix metalloproteinases for the treatment of heart failure with preserved ejection fraction.
